RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
  CAD
  CHF
  Clinical Trials
  Hypertension
  Myocardial Infarction
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Sep 15, 2017 - 4:49:58 AM
Cardiology Channel

subscribe to Cardiology newsletter
Latest Research : Cardiology

   EMAIL   |   PRINT
Diabetes drug can raise heart disease risk by 25 percent

Mar 20, 2011 - 3:11:07 PM

It found that Avandia could have led to an extra 431 deaths per 100,000 people, an extra 170 heart attacks and an extra 649 cases of heart failure.


 
[RxPG] Diabetes drug Avandia, which has been used by at least 50,000 people in Britain, increases the risk of heart disease by 23 percent and the risk of death by 14 percent.

A study of 810,000 people found that those taking Avandia were 23 percent more likely to suffer congestive heart failure and 14 percent more likely to die, compared to a similar medication.

In addition, they were 16 percent more likely to have a heart attack, the British Medical Journal reports.

Last September, the European Medicines Agency - suspended the licence for the drug after 10 years on the market, saying the evidence of its harmful effects had tipped the balance against it being prescribed, according to the Telegraph.

The latest study is further evidence supporting that decision. It analysed the results of 16 separate studies in 810,000 patients, of which 429,000 were on Avandia -- also known by its generic name rosiglitazone, and 381,000 who were on Actos -- also known as pioglitazone. Most were over the age of 60.

The drugs belong to a class that help control blood sugar levels in patients with Type 2 diabetes.

It found that Avandia could have led to an extra 431 deaths per 100,000 people, an extra 170 heart attacks and an extra 649 cases of heart failure.

University of East Anglia pharmacology lecturer Yoon Kong Loke, who led the study, warned that although the drug had been withdrawn in Britain, patients could still be affected by it.




Advertise in this space for $10 per month. Contact us today.


Related Cardiology News
New NIH-funded resource focuses on use of genomic variants in medical care
World Heart Day 2013
The higher the better?
Common blood pressure drug reduces aortic enlargement in Marfan syndrome
Cardiovascular risk factors highest in winter and lowest in summer
Quitting smoking drops heart attack risk to levels of never smokers
Study finds mechanical chest compressions are equally as effective as manual CPR
Impact of AF on stroke risk eliminated with multiple risk factors
Mass screening identifies untreated AF in 5% of 75-76 year olds
Diabetic stroke risk after AMI drops in 10 year period

Subscribe to Cardiology Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

Online ACLS Certification

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)